Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shipi Xiaoji formula (SPXJF) is a Traditional Chinese Medicine formulation being investigated as a novel ferroptosis inducer in hepatocellular carcinoma. According to research approaches in network pharmacology, SPXJF has been identified as having potential to induce ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, in HCC cells. The formula represents a multi-component herbal medicine consistent with TCM treatment principles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shipi Xiaoji formula.